Message: | Ostarine MK 2866 was developed by GTx, the drug originally developed by Merck & Co.GTx incorporated was incorporated in 1997 and licensed MK 2866.By 2007, MK 2866 was in Phase II trials, the same year GTx signed an exclusive license agreement with Merck for its SARM program. The two companies closed the deal in 2010.
In August 2011, a double-blind, placebo-controlled Phase II trial in older men and postmenopausal women demonstrated that MK 2866 demonstrated statistically significant improvements in overall lean body mass and physical function, while not as steroid-like Common side effects.
https://www.sarmshgpharm.com/sarms-list/mk2866/sarms-ostarine/ |